Tortorella, C., Solaro, C., Annovazzi, P., Boffa, L., Buscarinu, M. C., Buttari, F., Calabrese, M., Cavalla, P., Cocco, E., Cordioli, C., De Luca, G., Di Filippo, M., Fantozzi, R., Ferraro, D., Gajofatto, A., Gallo, A., Lanzillo, R., Laroni, A., Fermo, S. Lo, Malucchi, S., Maniscalco, G. T., Moccia, M., Nociti, V., Paolicelli, D., Pesci, I., Prosperini, L., Ragonese, P., Tomassini, V ![]() |
![]() |
PDF
- Accepted Post-Print Version
Download (226kB) |
Abstract
Abstract In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process. Aims The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice. Results The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the supervision of a medico-legal advisor, received the aegis of Italian Neurological Society (SIN) and constitutes a step toward a standardized decision process around DMTs in MS.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Publisher: | Springer Verlag (Germany) |
ISSN: | 1590-1874 |
Date of First Compliant Deposit: | 1 May 2020 |
Date of Acceptance: | 13 March 2020 |
Last Modified: | 14 Nov 2024 01:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/131377 |
Actions (repository staff only)
![]() |
Edit Item |